Ballantyne CM, et al. - In this phase 3, multicenter, randomized, double-blind, placebo-controlled study (CLEAR Tranquility) involving patients with a history of statin intolerance requiring additional low-density lipoprotein cholesterol (LDL-C) lowering, researchers tested the efficacy and safety of bempedoic acid when added to lipid-modifying therapy. They found that, compared with placebo, 28.5% more reduction in LDL-C was achieved with the addition of bempedoic acid to background lipid-modifying therapy that included ezetimibe. Good tolerability of bempedoic acid was demonstrated. Overall, in statin intolerant patients who require additional LDL-C lowering, bempedoic acid may serve as an oral therapeutic option complementary to ezetimibe.